Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD

Ameriprise Financial Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 397.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,748,403 shares of the biopharmaceutical company’s stock after buying an additional 5,392,191 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.54% of Gilead Sciences worth $748,147,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Sivik Global Healthcare LLC lifted its stake in Gilead Sciences by 25.0% in the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares during the period. One Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Invesco Ltd. grew its position in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares during the last quarter. Ariel Investments LLC increased its position in shares of Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares during the period. Finally, Simplify Asset Management Inc. raised its stake in shares of Gilead Sciences by 148.6% in the second quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock worth $5,864,000 after purchasing an additional 31,618 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the completion of the transaction, the chief executive officer owned 571,203 shares of the company’s stock, valued at approximately $72,280,027.62. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 135,757 shares of company stock valued at $16,616,127. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. HSBC upped their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.13.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $120.40 on Friday. The firm’s fifty day simple moving average is $121.89 and its 200-day simple moving average is $115.71. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $149.38 billion, a price-to-earnings ratio of 18.67, a PEG ratio of 0.68 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.